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Available online xxxxDiagnosis and treatment of systemic amyloidosis depend on accurate identiﬁcation of the speciﬁc amyloid ﬁbril
protein forming the tissue deposits. Conﬁrmation of monoclonal immunoglobulin light chain amyloidosis (AL),
requiring cytotoxic chemotherapy, and avoidance of such treatment in non-AL amyloidosis, are particularly im-
portant. Proteomic analysis characterises amyloid proteins directly. It complements immunohistochemical stain-
ing of amyloid to identify ﬁbril proteins and gene sequencing to identify mutations in the ﬁbril precursors.
However, proteomics sometimes detects more than one potentially amyloidogenic protein, especially immuno-
globulins and transthyretin which are abundant plasma proteins. Ambiguous results are most challenging in the
elderly as both AL and transthyretin (ATTR) amyloidosis are usually present in this group. We have lately de-
scribed a procedure for tissue decellularisation which retains the structure, integrity and composition of amyloid
but removes proteins that are not integratedwithin the deposits. Herewe show that use of this procedure before
proteomic analysis eliminates ambiguity and improves diagnostic accuracy.
Signiﬁcance: Unequivocal identiﬁcation of the protein causing amyloidosis disease is crucial for correct diagnosis
and treatment. As a proof of principle, we selected a number of cardiac and fat tissue biopsies from patients with
various types of amyloidosis and show that a classical procedure of decellularisation enhances the speciﬁcity of
the identiﬁcation of the culprit protein reducing ambiguity and the risk of misdiagnosis.
© 2017 Published by Elsevier B.V.Keywords:
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Amyloid typing1. Introduction
One of themajor therapeutic strategies of systemic amyloidosis con-
sists in reducing the production and thus the abundance of the protein
which aggregates to form extracellular amyloid deposits. Therapy is
therefore dictated by amyloid ﬁbril typing in each case [1]. Most crucial-
ly, the very toxic and expensive cytotoxic chemotherapy essential in AL
amyloidosis is not beneﬁcial in other forms of amyloidosis and can be
extremely dangerous [2]. Proteomic analysis of amyloid deposits pro-
vides direct chemical characterization of the proteins present and isd Digestive Health, University
K.
ry Unit, Centre for Amyloidosis
y College London, Rowland Hill
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7.06.016complementary to immunohistochemical staining for known amyloid
ﬁbril proteins and gene sequencing to identify known or potential
amyloidogenic mutations. It has been reported that proteomics unam-
biguously identiﬁes themajor amyloid constituent in the largemajority
of cases [3], but in some casesmore than one potentially amyloidogenic
protein, even though with different score, is detected in the amyloid
specimen and for these patients an accurate diagnosis can become
quite challenging [4,5]. Most commonly the ambiguity can be caused
by the co-presence in the specimen of both immunoglobulin light
chains and transthyretin, both of which are abundant in the plasma
and cause the two most common forms of systemic amyloidosis. Fur-
thermore, theprevalence ofwild-typeATTR amyloidosis, uniquely a dis-
ease of the elderly, has recently been recognised and monoclonal
gammopathy with increased production of monoclonal immunoglobu-
lin light chains, the precursor of AL amyloidﬁbrils, is common in this age
group [6]. Indeed, up to 20% of patients with ATTR amyloidosis have an
incidental monoclonal protein in serum or urine [7].roteomic typing by decellularisation of amyloid tissue biopsies, J Prot
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ly recommendeduse ofﬁneneedle fat aspiration biopsies [8] for diagno-
sis and typing of amyloid. Proteomic analysis of standard excision or
resection biopsies involves laser capturemicrodissection of the amyloid
deposits themselves, selectively concentrating the ﬁbrils, but this step is
omitted with ﬁne needle fat aspiration samples. Contamination by
abundant plasma proteins, not necessarily related to amyloid formation
in vivo, is common in these specimens.
We have lately demonstrated that application of tissue
decellularisation to amyloidotic organs and tissues leaves extracellular
matrix proteins and amyloid deposits intact [9]. Herewe show that sub-
jecting biopsies to a rapid tissue decellularisation protocol before diges-
tion and mass spectrometry (MS) analysis, eliminates background
contamination and enables unequivocal identiﬁcation of the actual am-
yloid ﬁbril protein.
2. Methods
2.1. Patients
Patients attending the National Amyloidosis Centre in the Centre for
Amyloidosis and Acute Phase Proteins at UCL, London, UK, all provided
informed written consent in accordance with the Declaration of Helsin-
ki. Endomyocardial biopsies were received from 3 patients. Patient 1: a
73 year old man with κmyeloma presented with periorbital bruising,
macroglossia and heart failure with amyloid cardiomyopathy. 99mTc-
3,3-diphosphono-1,2-propanodicarboxylic acid (99mTc-DPD) scan
showed Perugini grade 3 cardiac uptake but no visceral amyloid de-
posits were detected by serum amyloid P component (SAP) scintigra-
phy. No mutations were detected on sequencing of his TTR and APOA1
genes. His myeloma was treated with cyclophosphamide vincristine
dexamethasone (CVD) chemotherapy. Patient 2: a 65-year-old man
with heart failure and amyloid cardiomyopathy but no abnormality on
Tc–DPD or SAP scintigraphy, no monoclonal protein in serum or urine
and wild-type TTR and APOA1 genes. Patient 3: a 67-year-old man
with chronic lymphocytic leukaemia and a monoclonal κ paraprotein
who presented with heart failure, amyloid cardiomyopathy and auto-
nomic neuropathy. TC-DPD scan showed Perugini grade 2 uptake but
no visceral amyloid deposits were detected by SAP scintigraphy. TTR
gene sequencing showed that he was heterozygous for the known
amyloidogenicmutation encoding T60A TTR. Fat biopsies were received
from 7 other patients in which more than one potentially
amyloidogenic protein was detected in the untreated tissue specimen.
2.2. Laser capture microdissection and proteomic mass spectrometry
analysis
Sections (6 μm) of formalin-ﬁxed parafﬁn-embedded tissue on Di-
rector™ slides, stained with alkaline alcoholic Congo red (AMRESCO,
Solon, OH, USA) [10] and haematoxylin (Pioneer Research Chemicals,
Colchester, UK), were viewed under intense cross polarized light.
Areas showing the pathognomonic apple green birefringence of amy-
loid were excised by laser capture microdissection and trapped on ad-
hesive caps of microcentrifuge tubes. Following the method of
Rodriguez et al. [11], proteins were extracted from each sample into
10 mM Tris/1 mM EDTA/0.002% Zwittergent buffer solution (35 μl) by
heating (99 °C, 1.5 h) followed by sonication (1 h) and then digested
with trypsin (1.5 mg w/v) overnight (~18 h) at 37 °C. Each digested
samplewas reducedwith dithiothreitol (50 μg) at 99 °C for 5min, freeze
dried, reconstituted in 0.1% v/v triﬂuoroacetic acid in HPLC grade water
(20 μl) and analysed by HPLC-MSMS.
Tryptic digests were applied to a trap column (180 μm ID × 20 mm
bed, 5 μm Symmetry C18 packing; Waters Corporation, Massachusetts,
USA) and separated on a reverse phase column (100 μm ID × 150 mm
bed, 5 μm C18 packing; Nikkyo Technos Company Ltd., Tokyo, Japan)
using a linear gradient from 1% to 60% acetonitrile/water over 44 minPlease cite this article as: P.P. Mangione, et al., Increasing the accuracy of p
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tion boluses containing formic acid, ammonia, methanol and acetoni-
trile followed by a full solvent blank were run after each sample.
Nanoﬂow liquid chromatography-electrospray tandem MS was per-
formed using a Waters nanoACQUITY™ UPLC system (Waters Ltd.,
Elstree, Hertfordshire, UK) coupled to a Thermo Scientiﬁc Orbitrap
VelosMass Spectrometer (Thermo Electron, Bremen, Germany) operat-
ed in the positive ion mode. Each tryptic digest was analysed in three
technical replicates unless otherwise stated (Supplementary Table1).
Instrument control and data acquisition used Thermo Scientiﬁc
Xcalibur Version 2.1. MS data ﬁles were analysed using MASCOT soft-
ware (Matrix Science, London, UK) [12] to search the SwissProt data-
base. Searches were conducted with trypsin as the digestion enzyme
(with 2 missed cleavages) and oxidation of methionine set as a variable
modiﬁcation; mass tolerances were 10 ppm for precursor ions, 0.60 Da
for fragment ions with possible charge states of +2, +3 and +4. Pro-
tein identities were expressed in terms of MASCOT probability-based
scores with a signiﬁcance value set at p b 0.05 (http://www.
matrixscience.com/help/scoring_help.html).
In addition Mascot output data ﬁles were also analysed and validat-
ed by the use of Scaffold 4.6.1 (Proteome Software, Inc., Portland, OR).
This tool uses a Local False Discovery Rate (LFDR)-based scoring system
for peptide validation based on a Bayesian approach to conﬁrm peptide
probabilities. The likelihood of peptides is calculated on parent ionmass
accuracy and parent ion delta masses [13,14]. Filtering parameters for
protein identiﬁcation by Scaffold were set at a protein threshold conﬁ-
dence level N 99%, a minimum of 2 assigned peptides with a probability
N95%.
In addition, to increase conﬁdence in protein identiﬁcation and pep-
tide validation, Scaffold software was run using Mascot and X!Tandem
search engines.
A semi-quantitative analysis was performed on the group of fat aspi-
rates by considering the total number of spectra matched to a single
protein group (TS) [15]; TS values in the three replicates per sample
were averaged. Ratios of the resulting TS between non-amyloid and am-
yloid protein in both untreated and decellularised samples were calcu-
lated and plotted. In addition, we carried out a label free
quantiﬁcation (LFQ) of proteins using MaxQuant software (version
1.5.8.3), which is based on the ion intensities of the extracted ion chro-
matogram [16].
For the ﬁrst and the main search, peptide mass tolerances were
20 ppm and 4.5 ppm respectively, whereas for MS/MS the threshold
was 20 ppm. For the protein identiﬁcation, a minimum of 2 peptides
and at least 1 unique peptide were set. The searchwas performed in re-
vert decoy mode with peptide spectra matches false discovery rate
(PSM FDR), protein FDR and site decoy fraction set at 0.01. An average
of LFQ of 3 replicates for each experiment was determined and the
ratio between LFQ of non-amyloid and amyloid protein in untreated
and decellularised samples was calculated and plotted.
Statistical analysis for the group of 7 fat biopsies was performed by
using theMannWhitney test on GraphPad Prism 5 software (GraphPad
Prism Inc., San Diego, CA). Statistically signiﬁcant differences between
the untreated and decellularised TS (or LFQ) ratios are indicated by p
b 0.05.
2.3. Decellularisation protocol
Fresh, unﬁxed, snap frozen cardiac or adipose tissue biopsies were
decellularised by sequential washing with 500 mM NaCl containing
2mMcalcium chloride; 4%w/v sodiumdeoxycholate; and Tris-HCl con-
taining 140mMNaCl, 2 mM calcium chloride, pH 8.0 (all reagents from
Sigma-Aldrich, St. Louis, MO, USA). All the steps were carried out at
room temperature using a minimal volume of the respective buffer in
Eppendorf safe-lock tubes placed in a tissuelyser (Qiagen, Hilden, Ger-
many) at 25 Hz per 2 min. Typically two set of washings were repeated
for the tissue to become translucent. Decellularised cardiac biopsyroteomic typing by decellularisation of amyloid tissue biopsies, J Prot
3P.P. Mangione et al. / Journal of Proteomics xxx (2017) xxx–xxxspecimens were then formalin-ﬁxed, wax-embedded for Congo red
staining [10], laser dissection and proteomic MS analysis. In addition
fresh untreated and decellularised fat biopsies were digested withFig. 1. Amyloid in untreated and decellularised endomyocardial biopsy from patient 1. (A) Brig
ﬁxed, wax-embedded untreated and decellularised tissue. (B) Intense cross-polarized light vie
amyloid after decellularisation. Images from Leica DM4000 microscope with Leica DFC7000
decellularised (ii) biopsies after reduced SDS homogenous 15% PAGE.
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(2017), http://dx.doi.org/10.1016/j.jprot.2017.06.016trypsin (Promega, Madison,WI, USA) without prior ﬁxation or any pre-
vious processing and then analysed by liquid chromatography mass
spectrometry mass spectrometry (LCMSMS) as above.ht ﬁeld view showing Congophilic material in Congo red stained [10] sections of formalin-
w of same sections showing retention of the pathognomonic apple green birefringence of
T camera. Scale bar, 50 μm. (C) Immunoblot analysis of fresh unﬁxed untreated (i) or
roteomic typing by decellularisation of amyloid tissue biopsies, J Prot
Table 1
Proteomic MS analysis of untreated and decellularised cardiac (A) and fat (B) biopsies.
A
Cardiac
biopsy
Untreated Decellularised
Patient Amyloid
score mascot
Scaffold results Amyloid
score
mascot
Scaffold results
P
(%)
EUP EUS TS P
(%)
EUP EUS TS
1 κ, 184 N99 4 5 7 κ, 412 N99 5 6 13
TTR, 86 N99 3 3 4 TTR, 0 ND 0 0 0
2 λ, 180 N99 3 5 7 λ, 222 N99 6 8 12
κ, 107 ND 0 0 0 κ, 19 ND 0 0 0
3 TTR, 794 N99 10 14 21 TTR, 973 N99 10 13 30
B
Fat
aspirate
Untreated Decellularised
Patient Amyloid
score
mascot
Scaffold results Amyloid
score
mascot
Scaffold results
P
(%)
EUP EUS TS P
(%)
EUP EUS TS
4 λ, 755 N99 11 15 37 λ, 1788 N99 10 14 64
κ, 733 N99 8 12 22 κ, 539 N99 5 9 16
5 λ, 824 N99 12 17 40 λ, 1235 N99 11 17 56
TTR, 451 N99 8 10 13 TTR, 348 N99 7 8 9
6 λ, 221 N99 5 7 9 λ, 349 N99 6 8 18
κ, 39 N99 1 1 2 κ, 0 ND 0 0 0
7 λ, 301 N99 5 6 13 λ, 595 N99 7 10 25
TTR, 54 N99 1 1 1 TTR, 76 N99 1 1 1
8 λ, 465 N99 4 6 19 λ, 589 N99 5 7 22
κ, 252 N99 4 5 8 κ, 0 ND 0 0 0
9 TTR, 585 N99 7 8 12 TTR, 1758 N99 15 25 54
κ, 609 N99 5 7 15 κ, 230 N99 3 3 7
10 TTR, 693 N99 12 18 23 TTR, 236 N99 7 9 12
κ, 257 N99 4 6 10 κ, 33 N99 1 1 1
Proteins identiﬁed in each sample with Mascot score probabilities and Scaffold software
results. P: Protein identiﬁcation probability; EUP: Exclusive Unique Peptide count (num-
ber of uniquepeptides only associatedwith this protein); EUS: Exclusive Unique Spectrum
count (number of unique spectra only associated with this protein); TS: Total Spectrum
count (number of total spectra associated with this protein including those shared with
other proteins). ND: not detected. Mean of three technical replicates (see Supplementary
Table 1 for the complete list of values) are given for untreated and decellularised cardiac
biopsies except for untreated samples for patient 1 and 2 due to lack of material.
4 P.P. Mangione et al. / Journal of Proteomics xxx (2017) xxx–xxxAt this stage, the decellularisation does not allowa quantitativemea-
surement of the yield of amyloid at the end of the procedure. Qualitative
analysis carried out by microscopic analysis of Congo red stained
specimen, however, reveals that the intensity of the green birefringence
remains unaltered after the decellularisation.
2.4. Immunoblotting
Sections of unﬁxed cardiac biopsies, both untreated and
decellularised, were analysed by immunoblotting. Blotted-dry tissue
was ultrasonicated in the presence of Laemmli buffer (~10 μg tissue/
μl). After heating at 95 °C for 5 min and centrifugation for 10 min at
10,600g, reduced denatured supernatants (3 μl) were subjected to
SDS-PAGE in precast 15% gradient polyacrylamide gels (Excel, GE
Healthcare, Little Chalfont, UK) and then blotted onto an activated
PVDF membrane. Polyclonal rabbit anti-κ light chain (4 μg/ml, Dako,
Glostrup, Denmark) or sheep anti-human TTR (3 μg/ml, The Binding
Site, Birmingham, UK) antibodies were used to identify their cognate
antigens and were detected respectively by peroxidase-conjugated
polyclonal sheep anti-rabbit (25 × 10−3 μg/ml, Dako, Glostrup, Den-
mark) or anti-sheep (13 × 10−3 μg/ml) immunoglobulins, followed by
1:10,000 StrepTactin-HRP (Biorad, Hercules, CA, USA) for identiﬁcation
of the molecular weight standards (Precision Plus Protein WesternC,
Biorad, Hercules, CA, USA). Peroxidase activity was visualized using a
chemiluminescent substrate (Immobilon Western, Millipore, Billerica,
MA, USA) and a FluorChem M system (Proteinsimple, San Jose, CA,
USA).
3. Results and discussion
We demonstrated that decellularisation of whole amyloidotic
mouse organs fully retained the structure and functional properties of
the amyloid deposits in the extracellular space [9]. The procedure in-
volved sequential perfusion with water, detergent and DNase. Here
we adapted the procedure to decellularise very small human tissue bi-
opsies in order to improve the speciﬁcity of proteomic MS analysis for
amyloid typing. Only a limited number of sequential washing steps
were carried out using saline buffers and deoxycholate (see methods)
with a 1:40 ratio of biopsy weight/buffer volume; the process was ex-
tremely rapid and loss of tissue material was minimized. The effect of
decellurarisation on even tiny samples is exempliﬁed by the results
shown in Fig. 1 on the endomyocardial biopsy (Fig. 1) obtained from a
myeloma patient (patient 1) presenting an increased circulating free
monoclonal κ light chain concentration and, a high grade cardiac Tc-
DPD scan uptake that is a condition typical of ATTR amyloidosis, but
rarely seen in cardiac AL amyloidosis [7]. Mascot analysis of mass spec-
tra, after routine proteomic processing of ﬁxed tissue, showed both κ
light chain and TTR were present. Mascot output data were then com-
bined and analysed in Scaffold which assigned same probabilities
(N99%) to both κ and TTR (Table 1A, patient 1). This is a typical case in
which management and prognosis are radically different if the amyloid
protein is TTR or κ light chain. Fresh cardiac biopsy from patient 1 was
decellularised and, subsequently, ﬁxed and wax-embedded for Congo-
red staining, laser microdissection, trypsin digestion and MS analysis.
Bright ﬁeld imaging after the decellularisation procedure (Fig. 1A) con-
ﬁrmed removal of all the cells without affecting the abundant green bi-
refringent amyloid deposits in the Congo red stainedmaterial viewed in
cross-polarized light (Fig. 1B). A remarkable change in the results of
both immunoblotting and MS analysis was observed. The original blot
(Fig. 1C) showed κ light chains with heterogeneous masses, consistent
with full-length protein and fragments, and a single TTR band at the
mass of full length protomer. The anti-κ immunostaining pattern was
unchanged after decellularisation but the intensity of the TTR band
was notably reduced. Proteomic analysis of the decellularised sample
(Table 1A, patient 1) by Mascot and Scaffold conﬁrmed that κ light
chain was the only species detectable after decellularisation.Please cite this article as: P.P. Mangione, et al., Increasing the accuracy of p
(2017), http://dx.doi.org/10.1016/j.jprot.2017.06.016Mascot identiﬁed both κ and λ light chains in the cardiac biopsy of
patient 2 (Table 1A, patient 2) whereas Scaffold detected only λ. After
decellularisation, however, the Mascot score for λ light chain increased
whereas the κ light chain became undetectable. The Scaffold parame-
ters, after decellularisation, conﬁrmed that λ light chain was the only ﬁ-
bril protein. Although discrimination between κ and ʎ does not affect
current treatment for AL amyloidosis, this case shows that the proce-
dure allows unequivocal identiﬁcation of the ﬁbril protein.
Although in patient 3we found only TTR in untreated biopsy and the
amyloid typing was certain, we checked the protein composition after
decellularisation. Similar, or even better, scores for TTR were obtained
after treatment (Table 1A), thus conﬁrming that ﬁbrillar TTR is not re-
moved by this procedure. There was sufﬁcient material available from
this patient to estimate the variability of the procedure with three sep-
arate technical replicates of both control and decellularised tissue. For
the ﬁrst two patients three replicates could be carried out only for the
decellularised samples due to lack of material of the untreated samples.
In each case, decellularisation did not alter the identiﬁcation of the am-
yloid component (Supplementary Table 1) and retain at least two of the
so called signatures proteins for amyloid, serum amyloid P component
(SAP), apolipoprotein E, apolipoprotein A-IV [17], together with
vitronectin and clusterin [5] (Supplementary Table 2).
The decellularisation approach is clearly suitable for examining
unﬁxed frozen human tissue, however it would be unusual to obtain
such material in a normal clinical situation. In contrast, fresh fat aspi-
rates are routinely collected in our clinic, and so we investigatedroteomic typing by decellularisation of amyloid tissue biopsies, J Prot
Fig. 2. Improving speciﬁcity after decellularisation of fat aspirates. (A) In the presence of two potential amyloidosis-associated proteins identiﬁed byMascot and Scaffold, ratios between
soluble (a) and ﬁbrillar protein (b) were calculated using their corresponding total spectra count (TS) (see Table 1B) before (black circles) and after decellularisation (red triangles) of fat
aspirates. (B) Alternatively ion intensities of the extracted identiﬁed peaks (LFQ) of the two potential culprit proteinswere quantiﬁed usingMaxQuant software (Supplementary Table 3).
Ratios of the averaged LFQ values for the 3 replicates per sample were plotted as above. a: soluble protein; b: ﬁbrillar protein; black circles: untreated; red triangles: decellularised.
5P.P. Mangione et al. / Journal of Proteomics xxx (2017) xxx–xxxwhether the same simple decellularisation procedure could be applied
to aid proteomics analysis of fats.
The effect of decellularisation on fat aspirates is summarized in Table
1B and Supplementary Table 1. A semi-quantitative analysis was carried
out by considering the Scaffold total spectra count ratio between soluble
versus ﬁbrillar protein (Fig. 2A). In three cases (patients 4, 6 and 8), the
decellularisation improved the discrimination between k and ʎ light
chains as major constituent of the amyloid deposits. In other cases, in
which light chains and TTRwere both detectable in the tissue specimens
(patients 5, 7, 9 and 10), decellularisation increased speciﬁcity of amy-
loid typing as reﬂected in the score of the ﬁbrillar protein and the
ratio between the total peptides for the soluble and ﬁbrillar proteins
respectively.
In one case (patient 10), due to partial loss of tissue material, after
decellularisation the proteomic scores for both TTR and light chains di-
minished, but nevertheless the ratio of the respective peptides gives
clear indication on theﬁbrillar constituent. Improvement in the speciﬁc-
ity of amyloid typing was overall conﬁrmed when we considered the
area of the identiﬁed peaks (LFQ values by MaxQuant software in Sup-
plementary Table 3) rather than the total spectra count (Fig. 2B). Impact
of decellularisation was signiﬁcant (p b 0.05) on both TS and LFQ ratios
between soluble versus ﬁbrillar protein.
For all samples the retrospective clinical and pathologic review of
the cases was consistent with the proteomic results (Supplementary
Table 4).
Peptide spectra representing all the signature proteins for amyloid
[5,17,18] were present in the samples before and after decellularisation
(Supplementary Table 2).
4. Conclusion
It is widely accepted that proteomics is becoming an invaluable tool
for diagnosis of systemic amyloidosis [17,19] and represents a tech-
nique under rapid evolution in terms of pre-analytical treatment of
samples, technological progress of spectrometers, and bioinformatics
analysis of raw data. Our study mostly focuses on the possibility to get
better results just intervening on the pre-analytical treatment of the tis-
sue specimens.
The comparative analysis of proteomics of amyloid tissue
biopsies before and after decellularisation reveals that this is a
swift and straightforward procedure which improves the accuracy
and unequivocal identiﬁcation of amyloid ﬁbril type. It is particularly
helpful in cases where results of the current routine proteomic
procedure and of immunostaining are equivocal. Decellularisation
is readily applicable to both cardiac and fat biopsies. Fine needle fatPlease cite this article as: P.P. Mangione, et al., Increasing the accuracy of p
(2017), http://dx.doi.org/10.1016/j.jprot.2017.06.016aspiration is safer, simpler, minimally invasive and less expensive
than organ biopsy and laser microdissection is not required for the
proteomic analysis of the decellularised fat aspirates [17]. Ready
application of decellularisation to fat tissue specimen is particularly
important as, just recently, fat aspirate analysis was recommended
to get an earlier diagnosis of the disease and therefore a better
therapeutic response [8]. In conclusion, the increased sensitivity
and speciﬁcity of amyloid diagnosis enabled by decellularisation of
fresh unﬁxed fat aspirate samples, before they undergo proteomic
MS analysis, may represent a valuable procedure for the proteomic
characterization of amyloid deposits in tissue biopsies.
Decellularisation can be considered as a chemical microdissection
of the amyloid deposits where ﬁbrils, due to their very high stability,
do not dissociate and remain resistant to the extraction with buffer
containing detergents. Thermodynamic stability studies of prototyp-
ic amyloid ﬁbrils [20] suggest that these aggregates are more stable
than many other types of reversible protein-protein interactions
occurring in tissue. This property clearly represents an advantage
for diagnosis but is a major obstacle to the pharmacological removal
of amyloid in vivo.
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